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Abstract
BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be started is a
central, unresolved issue in the care of HIV-1-infected patients. In the absence of randomised trials, we
examined this question in prospective cohort studies. METHODS: We analysed data from 18 cohort
studies of patients with HIV. Antiretroviral-naive patients from 15 of these studies were eligible for
inclusion if they had started combination antiretroviral therapy (while AIDS-free, with a CD4 cell count
less than 550 cells per microL, and with no history of injecting drug use) on or after Jan 1, 1998. We
used data from patients followed up in seven of the cohorts in the era before the introduction of
combination therapy (1989-95) to estimate distributions of lead times (from the first CD4 cell count
measurement in an upper range to the upper threshold of a lower range) and unseen AIDS and death
events (occurring before the upper threshold of a lower CD4 cell count range is reached) in the absence
of treatment. These estimations were used to impute completed datasets in which lead times and unseen
AIDS and death events were added to data for treated patients in deferred therapy groups. We compared
the effect of deferred initiation of combination therapy with immediate initiation on rates of AIDS and
death, and on death alone, in adjacent CD4 cell count ranges of width 100 cells per microL. FINDINGS:
Data were obtained for 21 247 patients who were followed up during the era before the introduction of
combination therapy and 24 444 patients who were followed up from the start of treatment. Deferring
combination therapy until a CD4 cell count of 251-350 cells per microL was associated with higher rates
of AIDS and death than starting therapy in the range 351-450 cells per microL (hazard ratio [HR] 1.28,
95% CI 1.04-1.57). The adverse effect of deferring treatment increased with decreasing CD4 cell count
threshold. Deferred initiation of combination therapy was also associated with higher mortality rates,
although effects on mortality were less marked than effects on AIDS and death (HR 1.13, 0.80-1.60, for
deferred initiation of treatment at CD4 cell count 251-350 cells per microL compared with initiation at
351-450 cells per microL). INTERPRETATION: Our results suggest that 350 cells per microL should
be the minimum threshold for initiation of antiretroviral therapy, and should help to guide physicians
and patients in deciding when to start treatment.
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-
infected patients: a collaborative analysis of 18 HIV cohort studies
When To Start Consortium‡
Summary
Background—The CD4 cell count at which combination antiretroviral therapy should be started
is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of randomised
trials, we examined this question in prospective cohort studies.
Methods—We analysed data from 18 cohort studies of patients with HIV. Antiretroviral-naive
patients from 15 of these studies were eligible for inclusion if they had started combination
antiretroviral therapy (while AIDS-free, with a CD4 cell count less than 550 cells per μL, and with
no history of injecting drug use) on or after Jan 1, 1998. We used data from patients followed up in
seven of the cohorts in the era before the introduction of combination therapy (1989–95) to estimate
distributions of lead times (from the first CD4 cell count measurement in an upper range to the upper
threshold of a lower range) and unseen AIDS and death events (occurring before the upper threshold
of a lower CD4 cell count range is reached) in the absence of treatment. These estimations were used
to impute completed datasets in which lead times and unseen AIDS and death events were added to
data for treated patients in deferred therapy groups. We compared the effect of deferred initiation of
combination therapy with immediate initiation on rates of AIDS and death, and on death alone, in
adjacent CD4 cell count ranges of width 100 cells per μL.
Findings—Data were obtained for 21 247 patients who were followed up during the era before the
introduction of combination therapy and 24 444 patients who were followed up from the start of
treatment. Deferring combination therapy until a CD4 cell count of 251–350 cells per μL was
associated with higher rates of AIDS and death than starting therapy in the range 351–450 cells per
μL (hazard ratio [HR] 1·28, 95% CI 1·04–1·57). The adverse effect of deferring treatment increased
with decreasing CD4 cell count threshold. Deferred initiation of combination therapy was also
associated with higher mortality rates, although effects on mortality were less marked than effects
on AIDS and death (HR 1·13, 0·80–1·60, for deferred initiation of treatment at CD4 cell count 251–
350 cells per μL compared with initiation at 351–450 cells per μL).
Interpretation—Our results suggest that 350 cells per μL should be the minimum threshold for
initiation of antiretroviral therapy, and should help to guide physicians and patients in deciding when
to start treatment.
Funding—UK Medical Research Council.
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Introduction
Combination antiretroviral therapy has substantially reduced morbidity and mortality in
HIV-1-infected individuals since its introduction in 1996. Short-term randomised controlled
trials in immunodeficient patients showed that rates of AIDS or death were halved after
approximately 1 year of combination therapy compared with rates in patients treated with drugs
from only one antiretroviral drug class. The clinical effect of combination therapy has not been
examined in a long-term trial, but observational data suggest that this treatment reduces rates
of AIDS or death over several years, both in immunodeficient patients and in those with high
CD4 cell counts.
A central, unresolved issue is the CD4 cell count at which combination antiretroviral therapy
should be started in patients who have not yet had an AIDS-defining event. The best way to
address this question is to randomise AIDS-free HIV-1-infected patients to treatment with
combination therapy that is either started when the CD4 cell count is in an upper range or
deferred until the upper threshold of a lower CD4 cell count range is reached. So far, no such
randomised controlled trial has been done: the evidence is limited to a sub-study in the
Strategies for Management of Antiretroviral Therapy (SMART) trial, which suggested that
compared with initiation of treatment at a CD4 cell count of more than 350 cells per μL, delayed
initiation until the CD4 cell count was less than 250 cells per μL more than tripled the rate of
AIDS or death and, unexpectedly, increased the rate of other serious adverse events.
In the absence of evidence from randomised trials, the question of when to start combination
therapy is best addressed in prospective observational studies of HIV-1-infected individuals.
Most analyses of such data have compared rates of AIDS and death from the time that patients
started treatment (figure 1A). However, such comparisons are problematic because they do not
account for AIDS events or deaths that occur during the so-called lead time, before the upper
threshold of the lower CD4 cell count range is reached (figure 1B). These unseen events, as
well as lead times, will be ignored in analyses where patients' follow-up time is measured from
the start of treatment, which introduces lead-time bias.
We undertook a collaborative analysis of data from cohort studies to estimate the effect of
initiation of combination antiretroviral therapy in different CD4 cell count ranges.
Methods
Patients and procedures
We used data from seven cohort studies with patients followed up during the era before the
introduction of combination antiretroviral therapy, and data from the Antiretroviral Therapy
(ART) Cohort Collaboration of patients followed up from the start of treatment, to estimate
rates of AIDS or death in patients starting treatment in different CD4 cell count ranges, taking
into account the probability of progression to AIDS or death before the upper threshold of the
lower CD4 cell count range is reached. Patients whose presumed HIV transmission was by
injecting drug use were analysed separately, because they have a high prevalence of
comorbidities such as chronic hepatitis C and worse prognosis on combination therapy.
Analyses of progression before starting combination therapy included patients followed before
the introduction of this treatment (July 1, 1989, to Dec 31, 1995). We included patients with
a CD4 cell count in the range 0 cells per μL to 550 cells per μL from the following seven cohort
studies: the Multicenter AIDS Cohort Study (MACS), the Swiss HIV Cohort Study (SHCS),
the ANRS CO4 French Hospital Database on HIV (FHDH), the ANRS CO3 Aquitaine
Cohort, the Amsterdam Cohort Studies, the South Alberta Clinic, and the Concerted Action
on Seroconversion to AIDS and Death in Europe (CASCADE) collaboration (excluding
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patients who were also included in the other cohorts). Patients had CD4 cell count
measurements taken at scheduled clinics and were followed up for clinical AIDS events and
death. A small number of patients who started combination therapy before Jan 1, 1996, were
excluded.
Analyses of progression after the start of combination therapy included all patients enrolled in
one of 15 cohorts participating in the ART Cohort Collaboration who started treatment on or
after Jan 1, 1998, with a CD4 cell count between 0 cells per μL and 550 cells per μL. We
excluded patients if they had an AIDS diagnosis before starting combination therapy. The ART
Cohort Collaboration includes cohort studies from Europe and North America, and was
established with the aim of describing the prognosis of antiretroviral-naive patients starting
combination therapy. The study design has been described in detail elsewhere. Prospective
cohort studies were eligible for inclusion in the ART Cohort Collaboration if they had enrolled
at least 100 HIV-1-infected patients aged 16 years or older who had not previously received
antiretroviral therapy and who had started treatment with a combination of at least three drugs,
including nucleoside reverse transcriptase inhibitors, protease inhibitors, or non-nucleoside
reverse transcriptase inhibitors, with a median duration of follow-up of at least 1 year. All
cohorts provided anonymised data on a predefined set of demographic, laboratory, and clinical
variables.
The 15 cohorts from the ART Cohort Collaboration that contributed data for this analysis
included four previously mentioned cohorts as well as the AIDS Therapy Evaluation
Netherlands project (ATHENA), the Italian Cohort of Antiretroviral-Naive Patients
(ICONA), the Frankfurt HIV Cohort, the Köln-Bonn Cohort, the Collaborations in HIV
Outcomes Research United States (CHORUS), the 1917 Clinic Cohort University of
Birmingham, Alabama, the Veterans Aging Cohort Study (VACS), the London Royal Free
Hospital Cohort, the British Columbia Centre for Excellence in HIV/AIDS, the Proyecto para
la Informatizacion del Seguimiento Clinico epidemiologico de los pacientes con Infección por
VIH/SIDA (PISCIS), and the EuroSIDA study, which obtains data from 20 countries in Europe
and Argentina (excluding patients who were also included in other ART Cohort Collaboration
cohorts). Contributors to each cohort are listed in the webappendix (pp 1–8).
Statistical analysis
Data for patients who remained alive were censored at the patient's last visit, plus 50% of the
mean time between visits for each cohort. For example, if a cohort had a mean of 6 months
between follow-up visits, data were censored at the patient's last visit plus 3 months. Patients
with a gap of more than 1 year between clinic visits were deemed lost to follow-up and their
data were censored at the beginning of the gap plus 50% of the mean time between visits.
Follow-up of patients in the era before the introduction of combination antiretroviral therapy
was administratively censored on Dec 31, 1995, and, in patients starting treatment, at 6 years
after initiation of treatment or at the (cohort-specific) date of the close of the database.
We used data for patients receiving combination therapy to derive Kaplan-Meier estimates of
cumulative probabilities of progression to AIDS and death from the time of treatment initiation,
according to CD4 cell count at initiation. We used Cox regression to estimate naive hazard
ratios (HRs) for AIDS or death (ie, HRs based on analyses that ignored lead time and unseen
AIDS and death events) that compared individuals in different CD4 cell count categories at
the start of treatment. In sensitivity analyses, we examined whether adjustment for patient
characteristics at the time of treatment initiation altered these naive HRs.
To account for lead time and unseen AIDS and death events, we used a method described by
Cole and colleagues, in which missing data on lead time and unseen events in the deferred
initiation group are recovered by use of multiple imputation. Full details are given in the
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webappendix (p 9). We used data from before the introduction of combination therapy to model
the distribution of times from the first CD4 cell count measurement in the upper CD4 cell count
range to the upper threshold of the lower CD4 cell count range (ie, lead time) and the probability
of progression to AIDS or death before reaching the upper threshold of the lower CD4 cell
count range (ie, unseen events; webappendix p 10). We repeated all comparisons with death
alone as the endpoint, assuming that combination therapy has no effect on deaths for 2 weeks
and that an AIDS diagnosis will lead to immediate initiation of treatment. Therefore, in patients
receiving combination therapy, deaths within 2 weeks of initiation were excluded, whereas in
data from the era before combination therapy, deaths included in analyses were those before
the upper threshold of the lower CD4 cell count range was reached, or within 2 weeks of an
AIDS diagnosis. We examined whether progression rates differed between the earlier (1989–
91) and later (1992–95) years of the era before combination therapy, by separating follow-up
time and including interaction terms in Cox regression models. We used random-effects
regression models for log-transformed CD4 cell counts to estimate the median decline in CD4
cell counts during the era before combination therapy.
On the basis of the fitted distributions, imputation was used to create completed datasets, in
which lead times and unseen AIDS and death events were added to the data for combination
therapy, for patients in the deferred initiation group. We used Cox regression to estimate HRs
that compared deferred with immediate initiation of treatment for each completed dataset, then
combined these by use of Rubin's formula. We used generalised gamma distributions for the
lead times and unseen events, after redistributing patients with censored data according to the
proportions of patients that progressed to AIDS or death and that reached the upper threshold
of the lower CD4 cell count range to estimate the probability of progression before reaching
the threshold. We examined the proportional hazards assumption by comparing progression
rates in the first 2 years with rates from 2 years to the end of follow-up (6 years).
We compared deferred with immediate initiation of combination therapy in adjacent ranges of
width 100 cells per μL. We started with a comparison of initiation at 101–200 cells per μL
compared with deferred initiation at 0–100 cells per μL, then compared initiation at 126–225
cells per μL with deferred initiation at 26–125 cells per μL and, by use of successive increments
of 25 cells per μL, made similar comparisons up to initiation at 451–550 cells per μL with
deferred initiation at 351–450 cells per μL. We undertook sensitivity analyses restricted to
patients included in four cohorts that provided both data for patients in the era before
combination therapy and data for patients receiving combination therapy (ANRS CO4
FHDH, ANRS CO3 Aquitaine Cohort, Swiss HIV Cohort Study, and the South Alberta Clinic
Cohort). We also undertook further sensitivity analyses in which distributions of lead times
and unseen events were estimated on the assumption that treatment in the deferred initiation
group was started at the first CD4 cell count measurement in the lower range or, if there was
no such measurement, at the midpoint of the range. We also plotted HRs for the cumulative
effects of delayed initiation compared with initiation in the range 351–450 cells per μL, by
multiplying HRs for successive non-overlapping CD4 cell count ranges (251–350, 151–250,
and 51–150 cells per μL). 95% CIs for the plotted cumulative effects were obtained by use of
a Poisson approximation after decomposition of the variance into contributions from each of
the CD4 cell count groups. All analyses were done with SAS version 9 and Stata version 10.
Role of the funding source
The sponsor of the study had no role in the design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all data in
the study and had final responsibility for the decision to submit for publication.
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Results
21 247 AIDS-free patients with presumed transmission not by injecting drug use who were
followed up during the era before the introduction of combination antiretroviral therapy (ie,
between 1989 and 1995), and 24 444 such patients from the ART Cohort Collaboration who
were followed up from the start of combination therapy were included in the main analyses.
4159 (17%) patients were followed up for more than 6 years after the start of treatment (at
which time follow-up data were censored because fewer than 20% of patients on combination
therapy were followed for more than this length of time). Patient characteristics are shown in
table 1. Compared with patients starting treatment, those followed up in 1989–95 were younger,
more likely to be men who have sex with men, and more likely to develop AIDS or die during
follow-up. We found little evidence that progression rates differed between the earlier (1989–
91) and later (1992–95) years of the era before combination therapy (webappendix p 11). The
median annual decline in CD4 cell count during 1989–95 was 60 cells per μL per year (95%
CI 58–61). Among patients starting combination therapy, 9103 (37%) started treatment with
a CD4 cell count in the range 201–350 cells per μL, 5513 (23%) started in the range 101–200
cells per μL, and 5053 (21%) in the range 351–550 cells per μL.
As reported previously, the cumulative probability of AIDS and death increased substantially
with decreasing CD4 cell count at the time of treatment initiation (figure 2). However, this
finding does not necessarily imply that treatment should be started before CD4 cell counts
decline to the lower ranges, because this comparison does not account for lead time or unseen
AIDS and death events (figure 1).
Table 2 compares rates of progression to AIDS or death in adjacent CD4 cell count ranges of
width 100 cells per μL. The median decline in CD4 cell count from the first measurement in
the upper range to the upper threshold of the lower range varied from 48 cells per μL for upper
range 451–550 cells per μL to 61 cells per μL for upper range 101–200 cells per μL. Estimated
lead times increase with decreasing CD4 cell count. This finding occurs, in part, because the
variability of CD4 cell counts is greater at higher ranges than at lower ranges; therefore,
observed declines are more rapid. As expected, the estimated proportion of patients progressing
to AIDS or death before reaching the upper threshold of the lower CD4 cell count range (the
percentage of patients with unseen AIDS and death events) increases with decreasing CD4 cell
count.
Table 2 also shows naive HRs and HRs adjusted for lead time and unseen events for AIDS and
death for initiation of combination therapy that is deferred until a lower CD4 cell count range,
compared with initiation of treatment at a higher CD4 cell count range. Adjustment for age at
initiation, sex, and risk group (men who have sex with men versus other) did not substantially
affect naive HRs (webappendix p 11). Compared with initiation of treatment when CD4 cell
count is in the range 351–450 cells per μL, deferring treatment to 251–350 cells per μL leads
to increased rates of AIDS or death (adjusted HR 1·28, 95% CI 1·04–1·57). At the higher CD4
cell count ranges, there was little evidence to suggest that deferred initiation of treatment was
associated with higher rates of AIDS and death. The effect of accounting for unseen AIDS and
death events outweighs the effect of lead time in comparisons of lower CD4 cell count ranges,
so that adjusted HRs exceed naive HRs. By contrast, at higher CD4 cell counts, rates of unseen
events are lower, and approximately balance the effect of lead time, so that the naive and
adjusted HRs are similar. Figure 3 shows the successive increase in rates of AIDS or death as
combination therapy is deferred to lower CD4 cell count thresholds.
Table 3 shows that, as expected, mortality rates increase with declining CD4 cell count.
Compared with HRs for the combined endpoint of progression to AIDS and death, the HRs
for mortality alone have wider 95% CIs, because the number of deaths is smaller than the
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number of combined AIDS and death events. Deferred initiation of combination therapy was
associated with higher mortality rates, although effects on mortality were less marked than
effects on AIDS and death. The mortality HR for deferred initiation of treatment at CD4 cell
count 251–350 cells per μL compared with initiation at 351–450 cells per μL was 1·13 (0·80–
1·60): there was little evidence that deferred initiation of treatment was associated with
increased mortality rates in higher CD4 cell count ranges. The beneficial effects of earlier
initiation of treatment were greater in the first 2 years of follow-up than in the period from 2
to 6 years' follow-up, apart from in the highest CD4 cell count ranges (webappendix p 12).
We repeated analyses in patients with presumed transmission by injecting drug use. In 4605
such patients receiving combination therapy, there were 653 AIDS or death events (334 deaths)
during 15 141 years of follow-up. In 9860 patients followed during 1989–95, there were 905
AIDS or death events (823 deaths) during 27 182 years of follow-up. Estimated HRs for
deferring start of treatment to lower CD4 cell count ranges compared with starting at higher
ranges are shown in the webappendix (p 12). For comparisons in which the threshold CD4 cell
count was low, the estimated benefits of earlier initiation were lower for patients whose
presumed transmission was by injecting drug use than for patients in the main analyses. At
higher CD4 cell count thresholds, the estimated benefits of earlier initiation were generally
consistent with those found in the main analyses, although as expected (given that the numbers
of patients with transmission by injecting drug use were smaller than in the main analyses),
95% CIs were wide.
Four cohorts contributed data for patients receiving combination therapy (13 084 [54%]
patients) as well as data for patients followed up during 1989–95 (17 993 [85%] patients). The
results of sensitivity analyses for the combined AIDS and death endpoint, restricted to patients
from these cohorts, were consistent with the main analyses (webappendix p 13). Most HRs for
the adverse effect of deferred treatment were larger than those for patients in the main analyses,
particularly for low CD4 cell count ranges.
The webappendix (p 13) shows the results of sensitivity analyses in which distributions of lead
times and unseen events were estimated on the assumption that treatment in the deferred
initiation group was started at the first CD4 cell measurement in the lower range or, if there
was no such measurement, at the midpoint of the range. The effect of the resulting additional
unseen events outweighed the effect of the additional lead time, so that hazard ratios for the
adverse effect of deferring treatment on rates of AIDS and death generally increased.
Compared with start of treatment in the range 351–450 cells per μL, deferred initiation of
treatment at a CD4 cell count between 51 cells per μL and 150 cells per μL was associated
with an HR of 5·67 (4·83–6·65) for the combined endpoint of AIDS and death, and an HR of
2·24 (1·72–2·92) for mortality (figure 4). In the ART Cohort Collaboration, 37% of patients
started combination therapy with a CD4 cell count below 150 cells per μL.
Discussion
This collaborative analysis of data from over 45 000 patients who were followed up in cohort
studies in Europe and North America suggests that in AIDS-free HIV-1-infected individuals,
deferring the start of combination antiretroviral therapy until CD4 cell counts are in the range
251–350 cells per μL leads to increased rates of the combined endpoint of AIDS or death
compared with starting in the range 351–450 cells per μL. As expected, the excess of AIDS or
death associated with deferred initiation of combination therapy became more pronounced as
the CD4 cell count threshold for starting treatment decreased. Effects of deferring treatment
on mortality alone were less pronounced, but patterns were consistent with those for rates of
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the combined endpoint of AIDS or death. Beneficial effects of early initiation tended to be
greater during the first 2 years of follow-up than in the period from 2 to 6 years' follow-up.
By contrast with previous studies that have compared rates of progression to AIDS or death
from the time of initiation of combination antiretroviral therapy, we accounted for the
treatment-free time spent by patients when treatment is delayed, and for the events that occur
before initiation of treatment in these patients. Thus, our analyses aimed to estimate the
intervention effects that would be seen in studies in which patients were allocated to either
initiation of treatment in a higher CD4 cell count range or delayed initiation until reaching a
lower CD4 cell count range. Because of the large number of patients included in this
collaborative study, our analyses had reasonable power to detect differences in progression
rates. By contrast, previous studies that compared mortality rates in patients with immediate
initiation of treatment with rates in patients in whom treatment was deferred were limited by
a small number of endpoints. The analysis of the HIV Outpatient Study showed that mortality
was reduced by 39% in patients who started treatment with CD4 cell count 350–500 cells per
μL compared with patients who deferred treatment until after the CD4 cell count had fallen to
below 350 per μL; however, this result did not reach conventional levels of statistical
significance (p=0·17). Previous analyses that used the method described here to account for
lead time and unseen AIDS and death events were also based on much smaller numbers of
patients.
Since we combined data for large numbers of patients in this analysis, we were able to compare
narrow CD4 cell count strata, of width 100 cells per μL, with the aim of identifying CD4 cell
count ranges within which earlier initiation has beneficial effects on rates of AIDS and death.
Had we compared wider CD4 cell count ranges, HRs might have increased, at the cost of
reduced clinical relevance. For example, a comparison of initiation of treatment in the range
301–500 cells per μL with deferral to the range 101–300 cells per μL would compare some
patients who started at 490 cells per μL with some patients who started at 110 cells per μL.
Patients who had an AIDS event before the start of combination therapy were excluded because
they have worse prognosis and are likely to start treatment irrespective of their CD4 cell
count. Nevertheless, our analyses included patients from many countries from Europe and
North America who were treated in different settings. The range of patients was broad: men
and women, patients aged from 16 years to 90 years, and patients presumed to have been
infected through heterosexual sex as well as men who have sex with men. We analysed data
from patients infected by injecting drug use separately, to avoid possible confounding because
of comorbidities, deferred treatment, and non-adherence in these patients. HIV-infected
intravenous drug users have a high prevalence of comorbidities and worse prognosis after
combination antiretroviral therapy. Because our conclusions for this subgroup of patients were
similar to those for all patients, our results should be applicable to many patients starting or
considering combination therapy in developed countries. The clear disadvantages of delaying
initiation of treatment until CD4 count is below 200 cells per μL might also have implications
for resource-limited settings, where eligibility criteria for initiation of combination
artiretroviral therapy are often advanced immunodeficiency or clinical disease.
An important assumption made in these analyses is that progression rates and mortality in the
era before the introduction of combination antiretroviral therapy (ie, 1989–95), are an
appropriate reflection of what they would have been in the absence of this treatment in recent
years. During the 1990s, the introduction of chemoprophylaxis, immunisation, and better
strategies for the management of acute opportunistic infections contributed to prevention of
clinical progression and improvement of survival rates in HIV-1-infected patients. In particular,
the introduction of prophylaxis against Pneumocystis jirovecii pneumonia and against
Mycobacterium avium complex disease in 1993 were important developments. Although
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substantially less effective than combination antiretroviral therapy, monotherapy (mainly with
zidovudine) became available in the late 1980s, and dual therapy with two nucleoside reverse
transcriptase inhibitors became available during the mid-1990s. These factors will have acted
in opposite directions: rates of AIDS and death in 1989–91 might have been higher than
contemporary rates in the absence of treatment because of lower rates of prophylaxis, whereas
rates in 1992–95 might have been reduced because some patients were treated with
monotherapy or dual therapy. We suggest that biases introduced by these factors will have
been limited. First, both prophylaxis and treatment were used mainly in patients with CD4 cell
counts less than 200 cells per μL, in whom the adverse consequences of delayed initiation of
treatment are clear. Second, monotherapy was of only limited, transient benefit, and dual
therapy became widely available only during late 1994 and early 1995. Third, we found little
evidence that rates of AIDS and death differed between the earlier (1989–91) and later (1992–
95) years of the era before combination antiretroviral therapy within the different CD4 cell
count ranges. Some patients included in the dataset of patients receiving combination therapy
had an initial regimen that included an unboosted rather than boosted protease inhibitor, which
might have attenuated the beneficial effect of treatment in the early portion of follow-up.
As is the case for any observational study, our results might have been affected by confounding
and selection biases, if patient characteristics associated with deferred initiation of treatment
are also predictive of progression rates on or off therapy. We aimed to deal with such biases
by excluding patient groups known to have higher progression rates. As well as excluding
patients infected by injecting drug use and those who had an AIDS event before the start of
combination therapy, we excluded patients who started treatment before 1998, when regimens
were less effective than those now available. Nonetheless, our results might still be affected
by unmeasured confounding factors. A randomised controlled trial would overcome such
concerns; moreover, it could take into account factors outside the scope of our analysis, such
as non-AIDS-defining events, severe and non-severe AIDS events, and drug-related toxic
effects. Therefore, a more definitive answer to the question of when to start combination
therapy will only be given when results become available from randomised controlled trials,
such as the Strategic Timing of Antiretroviral Treatment (START) trial (registered with
ClinicalTrials.gov, number NCT00821171). This study aims to establish whether immediate
initiation of combination treatment is superior (in terms of morbidity and mortality) to deferral
of treatment until the CD4 cell count falls below 350 cells per μL in HIV-1-infected people
who are antiretroviral naive with a CD4 cell count greater than 500 cells per μL.
In the absence of definitive evidence from randomised controlled trials, it is necessary to rely
on observational evidence when formulating guidelines on the CD4 cell count at which
combination therapy should be started. When patients and their physicians consider starting
antiretroviral treatment, they must balance its beneficial effects on rates of progression to AIDS
and death with several other issues. Eradication of HIV from an individual is not currently
possible; therefore, treatment is expected to be lifelong. Antiretroviral drugs can be
inconvenient to take, and have side-effects that include nausea, diarrhoea, and headache.
Combination antiretroviral therapy is associated with serious toxic effects including
lipodystrophy and lipoatrophy syndromes, hepatitis, renal failure and mitochondrial toxicity,
and an increased risk of cardiovascular disease. However, these toxic effects are to an extent
avoidable through choice of drug regimen: for example, increases in cardiovascular risk seem
greater for protease inhibitors than for non-nucleoside reverse transcriptase inhibitors, and
lipoatrophy is associated with thymidine analogues. Further, the HR of 1·28 for the comparison
of deferring initiation of treatment to the CD4 cell count range 251–350 cells per μL with
initiation at 351–450 cells per μL represents only a small absolute difference in the risk of
AIDS or death over the follow-up period considered here.
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Recent results from the SMART trial of structured treatment interruptions have also brought
new perspectives to our understanding of the benefits and risks of combination antiretroviral
therapy. In that trial, patients who had started treatment at high CD4 cell counts and
subsequently had treatment interrupted had higher rates not only of AIDS and death, but also
of serious non-AIDS events such as myocardial infarction, stroke, liver cirrhosis, and renal
failure. The analyses presented in this report do not account for non-fatal serious non-AIDS
events, which might be the major causes of morbidity and subsequent mortality at higher CD4
cell counts. Non-AIDS deaths in untreated individuals might account for the early high
mortality HRs for deferred initiation compared with immediate initiation during the first 2
years of follow-up (webappendix p 12). Data from the EuroSIDA study show that rates of death
from non-AIDS causes declined substantially at the start of the era of combination antiretroviral
therapy.
Thus, our findings should help to guide physicians and patients in deciding when to start
antiretroviral treatment. The evolution of guidelines has been compared to the swings of a
pendulum, from initial enthusiasm for early treatment, through to caution because of concern
about toxic effects and the risk of resistance and loss of treatment options, to more recent calls
for earlier treatment. The International AIDS Society USA panel recommended in August,
2008, that antiretroviral therapy is started in individuals with CD4 cell counts less than 350
cells per μL, and that this decision should be individualised when the CD4 cell count is greater
than 350 cells per μL. Recent US and European guidelines make similar recommendations.
Because we found evidence that deferral of treatment until the patient's CD4 cell count is less
than 350 cells per μL was associated with increased progression rates, and in view of diminished
concerns about toxic effects and resistance, our results suggest that 350 cells per μL should be
the minimum threshold at which antiretroviral therapy is started.
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Figure 1.
Comparison of analyses from (A) initiation of treatment and (B) time of first CD4 cell count
measurement in the upper range
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Figure 2.
Cumulative probability of (A) AIDS or death or (B) death alone after initiation of combination
antiretroviral therapy, according to range of CD4 cell count at the time of treatment initiation
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Figure 3.
Adjusted hazard ratios for (A) AIDS or death and (B) death alone for initiation of combination
antiretroviral therapy at a lower CD4 cell count threshold (ie, deferred initiation) versus
initiation in a range up to 100 cells per μL higher
The horizontal axis shows the threshold values (upper limits of the CD4 cell count ranges in
the deferred initiation groups [from 351–450 cells per μL, in steps of 25 cells per μL, to 0–100
cells per μL]). See table 2 and table 3 for lists of hazard ratios and 95% CIs.
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Figure 4.
Hazard ratios for the cumulative effect of deferred initiation of combination antiretroviral
therapy for (A) AIDS or death and (B) death alone, compared with starting treatment at CD4
cell count range 351–450 cells per μL
The horizontal axis shows the upper limits of the lower CD4 cell count range (251–350 cells
per μL, 151–250 cells per μL, and 51–150 cells per μL).
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Table 1
Characteristics at baseline and events recorded during follow-up for patients in the era before the introduction of
combination antiretroviral therapy and for patients receiving combination therapy
Patients followed up in the era
before combination
antiretroviral therapy (n=21 
247)
Patients receiving combination
antiretroviral therapy (n=24 
444)
Age (years) 34 (28–41) 37 (31–45)
Female 4813 (23%) 7154 (29%)
CD4 cell count (cells per μL) 354 (264–448) 230 (130–330)
Log10 HIV-1 RNA NA 4·9 (4·4–5·3)
Transmission group*
Heterosexual sex 6961 (33%) 11 382 (51%)
Men who have sex with men 11 874 (56%) 8483 (38%)
Other/unknown 2412 (11%) 2485 (11%)
Year of enrolment
1989–90 5784 (27%) ..
1991–92 6586 (31%) ..
1993–95 8877 (42%) ..
1998–99 .. 7000 (29%)
2000–02 .. 9490 (39%)
2003–06 .. 7954 (33%)
Initial combination antiretroviral therapy regimen
Protease inhibitor-based triple regimen .. 116 44 (48%)
NNRTI-based triple regimen .. 8696 (36%)
NRTI only .. 2347 (10%)
Other† .. 1757 (7%)
AIDS and death during follow-up
Total follow-up (years) 68 253 81 071
Length of follow-up (years) 3·1 (1·9–4·5) 3·2 (1·5–5·3)
Development of AIDS 5356 (25%) 1860 (8%)
Deaths 3630 (17%) 808 (3%)
AIDS or death 5893 (28%) 2366 (10%)
NA=not available. NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside reverse transcriptase inhibitor. Data are n (%) or median
(IQR). Baseline is date of start of follow-up in the era before combination antiretroviral therapy, and date of start of treatment for patients receiving
combination therapy.
*
Excluding 2064 patients from the Veterans Aging Cohort Study, in whom transmission group was classified only as injecting drug use or other.
†
Non-standard regimen consisting of more than one protease inhibitor and/or NNRTI, or more than three drugs (excluding ritonavir-boosting of protease
inhibitors).
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